XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail (Tables)

Condensed Consolidated Financial Statements Detail (Tables)

6 Months Ended

Jun. 30, 2019

Condensed Consolidated Financial Statements Detail [Abstract]

Accrued and other liabilities consisted of the following (in thousands):

	June 30,		December 31,
	2019		2018
Accrued legal and accounting fees	$	169	$	396
Accrued restructuring		—		1,361
Accrued incentive compensation		162		152
Accrued payroll and other benefits		107		155
Other		177		318
Total	$	615	$	2,382

Outstanding Securities Considered Anti-Dilutive

Potentially dilutive securities are excluded from the calculation of diluted net loss per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share available to common stockholders (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Convertible preferred stock		6,256		5,003		6,256		5,003
Common stock options and RSUs		1,934		1,625		1,861		1,635
Warrants for common stock		28		21		27		19
Total		8,218		6,649		8,144		6,657